ZBD | $40,000,000 | (Jan 23, 2026)
Halcyon Futures | $4,200,000 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026) Certified by Founder
Lodge
Synthekine
start up
United States
- Menlo Park, California
- 06/02/2023
- Series C
- $100,000,000
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.
- Industry Biotechnology Research
- Website https://www.synthekine.com/
- LinkedIn https://www.linkedin.com/company/synthekine/
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)
AnswersNow | $40,000,000 | (Jan 22, 2026)
Claim Health | $4,400,000 | (Jan 22, 2026)
Nasdaq Private Market | $37,600,000 | (Jan 22, 2026)
PraxisPro | $6,000,000 | (Jan 22, 2026)